TransMedics Group, Inc. (TMDX)
| Market Cap | 781.04M |
| Revenue (ttm) | 29.94M |
| Net Income (ttm) | -29.98M |
| Shares Out | 27.62M |
| EPS (ttm) | -1.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,315 |
| Open | 27.86 |
| Previous Close | 28.22 |
| Day's Range | 26.88 - 28.03 |
| 52-Week Range | 11.51 - 49.50 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 46.40 (+69.1%) |
| Est. Earnings Date | Nov 3, 2021 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system tha...
Financial Performance
In 2020, TMDX's revenue was $25.64 million, an increase of 8.62% compared to the previous year's $23.60 million. Losses were -$28.75 million, -14.31% less than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 46.40, which is an increase of 69.10% from the latest price.
News
TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transp...
ANDOVER, Mass., Sept. 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.
TransMedics' OCS Heart System Scores FDA Approval
TransMedics Group Inc (NASDAQ: TMDX) has received FDA premarket approval (PMA) for its OCS Heart system. Related content: Benzinga's Full FDA Calendar.
TransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplan...
ANDOVER, Mass., Sept. 7, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
ANDOVER, Mass., Aug. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of -44.44% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Reports Second Quarter 2021 Financial Results
ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs
ANDOVER, Mass., July 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference
ANDOVER, Mass., July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021
ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
FDA Advisory Committee Gives Thumbs Up To TransMedics' OCS Liver System
The Gastroenterology and Urology Devices Panel of the FDA's Medical Devices Advisory Committee has issued a favorable vote to support the approval of TransMedics Group Inc's (NASDAQ:TMDX) OCS Liver Syst...
TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS L...
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Cho...
ANDOVER, Mass., June 8, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: TransMedics Group Q1 Earnings
Shares of TransMedics Group (NASDAQ:TMDX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 30.95% over the past year to ($0.29), whic...
TransMedics Reports First Quarter 2021 Financial Results
ANDOVER, Mass., May 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage...
1 Feel-Good Healthcare Stock That Could Turn Your Tax Return Into Riches
TransMedics is looking to disrupt an entire industry and help thousands of transplant patients in the U.S. in the process.
TransMedics to Report First Quarter 2021 Financial Results on May 4, 2021
ANDOVER, Mass., April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Stock Is Trading Higher After FDA Adcom Votes In Favor Of Its OCS Heart System
The FDA Advisory Committee has voted in favor of TransMedics Group Inc (NASDAQ: TMDX) after reviewing clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol (CAP) re...
TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System
ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...